Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
ANAPTYSBIO, INC (ANAB) director John A. Orwin reported the settlement of 1,300 Restricted Stock Units (RSUs) into 1,300 shares of Common Stock on September 15, 2026. Each RSU converted into one share for no cash consideration, bringing his directly held Common Stock position to 17,995 shares. The RSUs vest in three equal annual installments on September 15, 2024, 2025 and 2026, subject to continued service.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of AnaptysBio, Inc. common stock on a Schedule 13G/A. They collectively report holding 1,491,959 shares of common stock, representing 5.0% of the class, based on 29,608,481 shares outstanding as of June 22, 2026.
The shares are held in a managed account of Point72 Associates II, LLC (the Sirenia Account), for which Sirenia and Mr. Silverstein report shared voting and dispositive power over all 1,491,959 shares and no sole voting or dispositive power. The filers state that the ownership is reported without conceding beneficial ownership status under Section 13.
AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders on August 11, 2026 and reported the results of four proposals. Two Class III directors, Hollings Renton and John P. Schmid, were elected to three-year terms expiring at the 2029 annual meeting. Renton received 15,304,522 shares for and 6,613,642 withheld/abstaining votes, while Schmid received 20,314,669 shares for and 1,603,495 withheld/abstaining votes; each proposal had 2,084,465 broker non-votes. Stockholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2027, with 22,343,352 shares for and 1,640,401 against. They also gave non-binding advisory approval to named executive officer compensation with 21,274,791 shares for and approved an amendment to the 2017 Equity Incentive Plan with 15,563,882 shares for.
Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.
ANAPTYSBIO, INC reported that Chief Medical Officer Paul F. Lizzul received a grant of 16,667 Performance Stock Units on March 12, 2026. These performance-based units were earned after achievement of certified criteria, each representing a right to one share of common stock. The award vests 50% on March 12, 2027 and 50% on March 12, 2028, subject to his continued service, leaving him with 16,667 PSUs held directly.
Faga Daniel reported acquisition or exercise transactions in this Form 4 filing.
AnaptysBio, Inc. reported that President and CEO Daniel Faga received a grant of 53,334 performance stock units (PSUs), each representing one share of common stock. The PSUs were earned based on certified performance criteria and vest over two years: 50% on March 12, 2027 and 50% on March 12, 2028, subject to his continued service.
JOE ANTHONY WARE filed to sell common stock of ANAB through Morgan Stanley Smith Barney LLC Executive Financial Services. The notice covers 10,694 shares of common stock with an aggregate market value of $718,333.09, expected to be sold on or after July 13, 2026 on NASDAQ. The shares relate to a stock option exercise for cash from the issuer. In the preceding three months, 6,030 shares of common stock were sold on June 30, 2026 for total proceeds of $408,773.70.
ANAB affiliate filed a Form 144 reporting a proposed sale of 9,476 shares via a stock option exercise on 06/29/2026, to be effected for cash. The filing also lists multiple common stock dispositions by Dennis Mulroy across May–June 2026, showing transaction dates, share counts, and gross proceeds for each sale.